Research Article

Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study

Lianghe Jiao,1 Jing Wei,2 Jun Ye,3 and Chuanmeng Zhang3

1Department of Thyroid and Breast Surgery, Taizhou People’s Hospital, Taizhou, 225300 Jiangsu Province, China
2Department of Obstetrics and Gynecology, Taizhou People’s Hospital, Taizhou, 225300 Jiangsu Province, China
3The Center for Translational Medicine, Taizhou People’s Hospital, Taizhou, 225300 Jiangsu Province, China

Correspondence should be addressed to Chuanmeng Zhang; 244073124@qq.com

Received 30 December 2019; Revised 5 June 2020; Accepted 22 February 2021; Published 4 March 2021

Academic Editor: Wen-Jun Tu

Copyright © 2021 Lianghe Jiao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background and Aim. Peroxiredoxin-1 (PRDX1) has been reported to be abnormally expressed in various malignancies. However, the prognostic role of PRDX1 in human solid tumors remains controversial. We performed this meta-analysis to accurately assess the prognostic significance of PRDX1 protein in patients with solid tumors. Methods. We comprehensively searched electronic databases, namely, PubMed, Web of Science, EMBASE, Chinese National Knowledge Infrastructure (CNKI), and WanFang databases up to December 2019. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to evaluate the association between PRDX1 protein expression and the survival of patients with solid tumors. Odds ratios (ORs) with 95% CIs were pooled to estimate the correlation between PRDX1 protein expression and clinicopathologic characteristics in the patients. Results. Seventeen cohort studies that involved 2,858 patients were included in this meta-analysis. The pooled results indicated that positive PRDX1 expression was related to poor overall survival (HR = 1.68, 95% CI: 1.24–2.27, P = 0.001) and disease-free survival (HR = 1.88, 95% CI: 1.31–2.70, P = 0.001). In addition, high PRDX1 expression was associated with large tumor size (OR = 1.67, 95% CI: 1.07–2.68, P = 0.025), advanced TNM stage (OR = 2.26, 95% CI: 1.24–4.13, P = 0.008), and poor tumor differentiation (OR = 0.59, 95% CI: 0.44–0.81, P = 0.001). Conclusions. PRDX1 overexpression is associated with poor outcomes of cancers and may serve as a prognostic biomarker for malignant patients. Hence, PRDX1 could be a new target for antitumor therapy.

1. Introduction

Cancer is one of the leading contributors to morbidity and mortality, with approximately 1,735,350 new cancer cases and 609,640 cancer-related deaths reported in the United States in 2018 [1]. Despite great advances in early detection and comprehensive treatment in recent years, most cancers still have poor prognosis [2, 3]. Early diagnosis and treatment monitoring can improve the prognosis of patients with cancer [4]. However, most cancer biomarkers lack sensitivity and specificity [5]. Therefore, identifying novel prognostic biomarkers is urgently needed not only for predicting outcomes but also for providing therapeutic targets for patients with cancer.

Reactive oxygen species (ROS) is involved in various physiological and pathological reactions in mammalian cells and plays a critical role in some diseases, including certain cancers [6, 7]. Peroxiredoxins (PRDXs) are a family of redox regulating proteins that could reduce ROS and maintain the stability of hydrogen peroxide in cells [8]. Meanwhile, these proteins can also inhibit ROS-induced tumor cell apoptosis and promote tumor cell survival. The mammalian PRDX family consists of six members (PRDX1 to PRDX6), which can be divided into three subgroups according to the number of cysteine residues: typical 2-cysteine (PRDX1–4), atypical 2-cysteine (PRDX5), and 1-cysteine (PRDX6) proteins [9]. Recent studies have reported that PRDXs are upregulated in various types of cancer.
and closely related to tumor progression, recurrence, and prognosis [10–14]. Thus, PRDXs have been identified as potential predictive and therapeutic biomarkers for cancer.

Peroxisiredoxin-1 (PRDX1) is an affiliate of the PRDX antioxidant protein superfamily [15]. PRDX1 activity is implicated in several biological processes, such as cell differentiation, proliferation, and apoptosis [16]. In the nucleus, PRDX1 influences biological activities of gene regulation by associating with various transcription factors, including p53, androgen receptor (AR), and nuclear factor kappa B (NF-κB), and then induces or inhibits cell death [8, 17, 18]. In the cytoplasm, PRDX1 shows antiapoptotic potential by interacting with an ROS-dependent signaling pathway [19]. An increasing number of studies have reported the association of high PRDX1 protein expression level with poor prognosis in patients with solid tumors. However, several publications revealed that the correlation is nonsignificant or even reversed. Thus, the real value of PRDX1 in predicting the prognosis of solid tumors remains controversial. In this regard, a meta-analysis is needed to determine the prognostic value of PRDX1 protein expression in patients with solid tumors.

2. Materials and Methods

2.1. Search Strategy. We performed this meta-analysis in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. The PubMed, Web of Science, EMBASE, Chinese National Knowledge Infrastructure (CNKI), and WanFang databases (up to November 2019) were systematically searched with the following keywords: (“peroxiredoxin-1” or “prdx1” or “prx1”), and (“tumor” or “cancer” or “carcinoma” or “neoplasm”), and (“prognosis” or “outcome” or “survival”). Manual searches were also conducted on the reference lists of the original articles to identify additional studies. Full-text articles published in English or Chinese were included.

2.2. Inclusion and Exclusion Criteria. Studies were enrolled according to the following criteria: (1) solid tumors were diagnosed by histopathology; (2) studies assessed the relationship between PRDX1 and prognostic outcomes, including overall survival (OS) or disease-free survival (DFS); (3) PRDX1 protein expression was detected in cancer tissues by immunohistochemistry stain or reverse phase protein array (RPPA) analysis and categorized into “high” and “low” groups; and (4) hazard ratios (HRs) with corresponding 95% confidence intervals (95% CIs) can be extracted directly or estimated with sufficient information. Articles were excluded according to the following criteria: (1) letters, reviews, abstracts, case reports, editorials, expert opinions, or animal experiments; (2) studies without sufficient information for estimating HRs with corresponding 95% CIs; (3) participants were not divided into two groups according to PRDX1 expression; and (4) studies with a sample size of less than 50.

2.3. Data Extraction and Quality Assessment. Data from each study were evaluated and extracted independently by two investigators (JLH and WJ). Any disagreement was resolved by a consensus with a third investigator (ZCM). The following information was collected in this meta-analysis: first author’s name, publication year, country, cancer type, TNM stage, sample size, follow-up time, OS and DFS, and HR estimation with 95% CI. In studies that reported univariate and multivariate HR estimations, only the latter was selected because it considers confounding factors and is more accurate.

The quality of eligible studies was assessed independently by two authors (JLH and WJ) according to the Newcastle-Ottawa Scale (NOS). Any disagreement was resolved through discussion with another investigator (YJ). Each study was assigned an overall score ranging from 0 to 9 based on quality of selection, comparability, exposure, and outcome assessment. Investigations with scores higher than or equal to 6 were regarded as high-quality research.

2.4. Statistical analysis. The Stata 12.0 (STATA Corp., College Station, TX) software was used for all statistical analyses. The combined HRs and their 95% CIs were calculated to evaluate the relationship between PRDX1 expression and patient survival. For the overall results, HR and 95% CI greater than 1 indicated poor prognosis in patients with PRDX1 overexpression. Moreover, pooled odds ratio (OR) and their 95% CI were applied to assess the association between PRDX1 expression and the clinicopathological parameters of solid tumors. Heterogeneity among individual studies was analyzed using chi-squared Q test and I-squared statistical test. When the results ($I^2 > 50\%$ or $P < 0.05$) indicated heterogeneity, the random effects model was applied for the meta-analysis; otherwise, the fixed effects model was adapted. Metagression and subgroup analyses were conducted on studies sorted into subgroups according to similar variables. Sensitivity analysis was performed to verify the stability of the synthesis results by sequentially omitting each individual study. Publication bias was also statistically evaluated using Egger’s test and visually assessed with a funnel plot. In case of significant publication bias, the trim-and-fill method was applied to validate the robustness of the summary results.

3. Results

3.1. Literature Search and Included Studies. A total of 227 records were retrieved from the PubMed, Web of Science, EMBASE, CNKI, and WanFang databases by using the above mentioned search strategy; of which, 94 studies were excluded because of duplicate records. And then 95 articles were removed because of obvious irrelevance. After screening the titles and abstracts, 27 papers were identified for full-text review. Finally, 15 articles met the inclusion criteria and were included in the meta-analysis. The study selection process is shown in Figure 1.

The basic characteristics of each article are summarized in Table 1. Among the 15 articles, 17 cohorts involving 2,858 patients were included, with sample sizes ranging from 55 to 712. All the included articles were cohort studies published between 2007 and 2019. These studies included patients from various regions who were diagnosed with 11 different types of cancer: ovarian cancer (OC) [8, 12], osteosarcoma (OSC) [20], colorectal cancer (CRC) [21], gastric
3.2. Correlation between PRDX1 and Clinicopathological Features. To analyze the role of PRDX1 protein expression as a prognostic biomarker for solid tumors, we first investigated its correlation with clinicopathological features. Fifteen cohorts comprising 1,907 patients reported the relationship between PRDX1 expression and tumor size, and the pooled results indicated that high expression of PRDX1 was correlated with large tumor size (OR = 1.69, 95% CI: 1.07-2.68, P = 0.025, random effects). Moreover, PRDX1 overexpression had a significant association with advanced TNM stage (OR = 2.26, 95% CI: 1.24-4.13, P = 0.008, random effects) and poor tumor differentiation (OR = 0.59, 95% CI: 0.44-0.81, P = 0.001, fixed effects). However, PRDX1 expression was not related to age (OR = 0.99, 95% CI: 0.73-1.36, P = 0.966, random effects), gender (OR = 0.93, 95% CI: 0.74-1.17, P = 0.514, fixed effects), depth of invasion (OR = 1.11, 95% CI: 0.37-3.38, P = 0.854, random effects), lymph node metastasis (OR = 1.47, 95% CI: 0.93–2.34, P = 0.100, random effects), and distant metastasis (OR = 1.94, 95% CI: 0.84-4.47, P = 0.120, fixed effects). The results are shown in Table 2.

3.3. Impact of PRDX1 on Prognosis. The main results of this meta-analysis are listed in Table 3. Seventeen cohorts involving 2,858 patients were used to assess the relationship between PRDX1 protein expression and OS, and 10 cohorts used DFS as the endpoint. For OS, the random effects model was applied to pool the HRs and 95% CIs because of extreme heterogeneity (I² = 82.9%, P < 0.001). The pooled results indicated that PRDX1 overexpression was significantly related to poor OS (HR = 1.68, 95% CI: 1.24-2.27, random effects, Figure 2). For DFS, the results showed the association of positive PRDX1 expression with unfavorable DFS (HR = 1.88, 95% CI: 1.31-2.70, random effects, Figure 3), and with significant heterogeneity (I² = 76.8%, P < 0.001).

3.4. Subgroup and Metaregression Analyses for OS. Considering the significant heterogeneity among the studies, we conducted subgroup and metaregression analyses by focusing on study region, cancer type, TNM stage, sample size, and analysis method to explore sources of heterogeneity for OS (Table 3).

Subgroup analysis of the study region indicated that PRDX1 overexpression was significantly related to worse OS in eastern countries (HR = 1.79, 95% CI: 1.24-2.58, P = 0.002, random effects) but not in western countries (HR = 1.39, 95% CI: 0.78-2.48, P = 0.267, random effects). Subgroup analysis based on cancer type suggested that high PRDX1 expression predicted poor OS in patients with OC (HR = 4.60, 95% CI: 2.05-10.34, P < 0.001, fixed effects), OSC (HR = 2.07, 95% CI: 1.43-2.98, P < 0.001, fixed effects), GC (HR = 2.00, 95% CI: 1.44-2.79, P < 0.001, fixed effects), and others (HR = 2.27, 95% CI: 1.72-3.00, P < 0.001, fixed effects). Nevertheless, no significant relationship was observed between PRDX1 expression and OS in patients with CCA (HR = 1.23, 95% CI: 0.32-4.69, P = 0.757, random effects), ESCC (HR = 0.82, 95% CI: 0.45-1.50, P = 0.521, random effects), and BC (HR = 0.83, 95% CI: 0.66-1.04, P = 0.111, fixed effects). With regard to TNM stage, the results showed the predictive role of PRDX1 positive expression on unfavorable OS in patients with cancer of stages I-IV (HR = 2.03, 95% CI: 1.38-2.98, P < 0.757, random effects), and I (HR = 2.41, 95% CI: 1.29-4.50, P = 0.006, random effects), but not in those with stages I-III (HR = 1.27, 95% CI: 0.77-2.10, P = 0.341, random effects), and none reported (HR = 0.66, 95% CI: 0.50-0.88, P = 0.004, random effects). When the cohorts were grouped by sample size, high PRDX1 expression was associated with worse OS for small samples but better OS for large sample sizes. Finally, the subgroup analysis suggested the close association of PRDX1 overexpression with worse OS in the multivariate analysis (HR = 1.24, 95% CI: 0.61-2.53, P = 0.557, random effects). Further metaregression analysis revealed that sample size (P = 0.010) and analysis method (P = 0.034) may be important factors for heterogeneity.
| Study         | Study region | Duration | Cancer type | TNM stage | Follow-up (months) | Number | Technology | PRDX1-high (%) | Analysis method     | HR (95% CI)       | Language | Quality |
|--------------|--------------|----------|-------------|-----------|-------------------|--------|------------|----------------|-------------------|-------------------|----------|---------|
| Sienkow J 2019 | Poland       | 2003-2010 | OC          | I-IV      | Mean 60.23        | 55     | IHC        | 11 (20.0%)     | Multivariate       | OS: 3.571 (1.408-9.091) DFS: 2.632 (1.111-6.250) | English | 8       |
| Cai AL (T) 2018 | China        | 2007-2010 | OSC         | I-III     | Mean 63           | 110    | IHC        | 66 (60.0%)     | Multivariate       | OS: 1.938 (1.197-3.138) DFS: 1.845 (1.191-2.856) | English | 7       |
| Cai AL (V) 2018 | China        | 2007-2010 | OSC         | I-III     | Mean 63           | 90     | IHC        | 59 (65.6%)     | Multivariate       | OS: 2.261 (1.288-3.970) DFS: 2.213 (1.374-3.564) | English | 7       |
| Li HX 2018    | China        | 2009-2012 | CRC         | I-IV      | NR                | 60     | IHC        | 42 (70.0%)     | Univariate         | OS: 1.754 (1.010-3.046) | English | 6       |
| Zheng MJ 2018 | China        | 2008-2012 | OC          | I-IV      | Up to 2017.9      | 101    | IHC        | 17 (16.8%)     | Multivariate       | OS: 10.033 (1.956-51.462) | English | 8       |
| Yu W 2018     | China        | 2008-2012 | GC          | I-IV      | NR                | 189    | IHC        | 127 (67.2%)    | Multivariate       | OS: 2.433 (1.429-4.132) DFS: 2.469 (1.456-4.184) | English | 7       |
| Zhou J 2015   | China        | 2004-2008 | CCA         | I-IV      | Median 16         | 88     | IHC        | 53 (60.2%)     | Multivariate       | OS: 2.597 (1.114-6.061) DFS: 1.344 (0.603-2.994) | English | 8       |
| Wu JP 2015    | China        | 2005-2014 | ESCC        | I-IV      | NR                | 144    | IHC        | 96 (66.7%)     | Multivariate       | OS: 1.192 (0.616-2.304) | English | 7       |
| Cai CY 2015   | China        | 2008-2011 | PC          | I-IV      | Median 13.5       | 86     | IHC        | 64 (74.4%)     | Multivariate       | OS: 3.162 (1.425-7.018) DFS: 4.805 (2.136-10.812) | Chinese | 7       |
| Xu DY 2014    | China        | 2001-2003 | GC          | I-IV      | Median 30         | 120    | IHC        | 70 (58.3%)     | Univariate         | OS: 1.769 (1.120-2.609) | English | 8       |
| O'Leary PC (RPPA) 2014 | USA, Spain, Canada | NR | BC | I-III | NR | 712 | RPPA | 356 (50.0%) | Multivariate | O'S: 0.93 (0.66-1.31) DFS: 0.94 (0.65-1.35) | English | 6       |
| O'Leary PC (TMA) 2014 | Sweden       | 1987-1992 | BC          | I-III     | Median 11         | 442    | IHC        | 221 (50.0%)    | Multivariate       | OS: 0.76 (0.56-1.03) DFS: 0.78 (0.52-1.16) | English | 7       |
| Sun QK 2014   | China        | 2006-2009 | HCC         | I-IV      | Median 24         | 76     | IHC        | 56 (73.7%)     | Multivariate       | OS: 2.897 (1.355-6.194) DFS: 3.268 (1.532-6.971) | English | 8       |
| Li J 2013     | China        | 2001-2009 | GBC         | I-IV      | NR                | 80     | IHC        | 42 (52.5%)     | Multivariate       | OS: 2.123 (1.266-3.562) | English | 7       |
| Yonglithipagon P 2012 | Thailand | NR | CCA | NR | NR | 301 | IHC | 102 (33.9%) | Multivariate | OS: 0.662 (0.498-0.877) | English | 7       |
| Kim JH 2007   | USA          | 1993-2002 | NSCLC       | I         | Median 70         | 90     | IHC        | 60 (66.7%)     | Multivariate       | OS: 2.409 (1.290-4.498) DFS: 2.327 (1.312-4.128) | English | 8       |
| Hoshino I 2007 | Japan        | NR        | ESCC        | I-IV      | NR                | 114    | IHC        | 41 (36.0%)     | Univariate         | OS: 0.640 (0.436-0.937) | English | 6       |

OC: ovarian cancer; OSC: osteosarcoma; CRC: colorectal cancer; GC: gastric cancer; CCA: cholangiocarcinoma; ESCC: esophageal squamous cell carcinoma; PC: pancreatic cancer; BC: breast cancer; HCC: hepatocellular carcinoma; GBC: gallbladder cancer; NSCLC: non-small cell lung cancer; OS overall survival; DFS: disease-free survival; HR: hazard ratio; CI: confidence interval; NR: none reported; T: Training cohort; V: Validation cohort; RPPA: reverse phase protein array; TMA: microarray; IHC: immunohistochemistry.
3.5 Sensitivity Analysis and Publication Bias. Sensitivity analysis was performed to assess the robustness of our results by sequentially omitting each individual cohort. No significant change was detected in the combined HR estimates of OS (Figure 4(a)) and DFS (Figure 4(b)). This finding indicated that our results were stable and reliable.

For OS, significant bias was found by Begg’s test ($P = 0.002$) and Egger’s test ($P < 0.001$). Furthermore, the funnel plot visually showed an apparent asymmetry (Figure 5(a)). The trim-and-fill analysis indicated that three unpublished studies were needed to neutralize the potential bias (Figure 5(b)). The combined results were slightly changed but remained significant.

| Categories                        | Trials (patients) | OR (95% CI)     | $I^2$ (%) | $P_h$  | Z    | $P_m$ | $P$   |
|-----------------------------------|-------------------|-----------------|----------|--------|------|-------|-------|
| OS (all)                          | 17 (2858)         | 1.68 (1.24-2.27)$^R$ | 82.9%    | <0.001 | 3.35 | 0.001 | 0.474 |
| Study region                      |                   |                 |          |        |      |       |       |
| Eastern countries                 | 13 (1559)         | 1.79 (1.24-2.58)$^R$ | 83.1%    | <0.001 | 3.11 | 0.002 |        |
| Western countries                 | 4 (1299)          | 1.39 (0.78-2.48)$^R$ | 83.4%    | <0.001 | 1.11 | 0.267 |        |
| Cancer type                       |                   |                 |          |        |      |       | 0.641 |
| OC                                | 2 (156)           | 4.60 (2.05-10.34)$^F$ | 13.6%    | 0.282  | 3.69 | <0.001|       |
| OSC                               | 2 (200)           | 2.07 (1.43-2.98)$^F$ | 0.0%     | 0.683  | 3.89 | <0.001|       |
| GC                                | 2 (309)           | 2.00 (1.44-2.79)$^F$ | 0.0%     | 0.357  | 4.11 | <0.001|       |
| CCA                               | 2 (389)           | 1.23 (0.32-4.69)$^R$ | 88.9%    | 0.003  | 0.31 | 0.757 |        |
| ESCC                              | 2 (258)           | 0.82 (0.45-1.50)$^R$ | 60.9%    | 0.110  | 0.64 | 0.521 |        |
| BC                                | 2 (1154)          | 0.83 (0.66-1.04)$^F$ | 0.0%     | 0.388  | 1.60 | 0.111 |        |
| Others                            | 5 (392)           | 2.27 (1.72-3.00)$^F$ | 0.0%     | 0.736  | 5.77 | <0.001|       |
| TNM stage                         |                   |                 |          |        |      |       | 0.601 |
| I-IV                              | 11 (1113)         | 2.03 (1.38-2.98)$^R$ | 75.4%    | 0.001  | 3.62 | <0.001|       |
| I-III                             | 4 (1354)          | 1.27 (0.77-2.10)$^R$ | 83.4%    | <0.001 | 0.95 | 0.341 |       |
| I                                 | 1 (90)            | 2.41 (1.29-4.50)$^R$ | —        | —      | 2.76 | 0.006 |       |
| NR                                | 1 (301)           | 0.66 (0.50-0.88)$^R$ | —        | —      | 2.86 | 0.004 |       |
| Sample size                       |                   |                 |          |        |      |       | 0.010 |
| ≥300                              | 3 (1455)          | 0.76 (0.64-0.91)$^F$ | 11.0%    | 0.325  | 8.96 | <0.001|       |
| <300                              | 13 (1403)         | 2.03 (1.51-2.74)$^R$ | 69.9%    | 0.001  | 4.67 | <0.001|       |
| Analysis method                   |                   |                 |          |        |      |       | 0.034 |
| Multivariate                      | 14 (2564)         | 1.82 (1.28-2.58)$^R$ | 83.4%    | <0.001 | 3.34 | 0.001 |       |
| Univariate                        | 3 (294)           | 1.24 (0.61-2.53)$^R$ | 86.9%    | <0.001 | 0.59 | 0.555 |       |
| DFS (all)                         | 10 (1908)         | 1.88 (1.31-2.70)$^R$ | 76.8%    | <0.001 | 3.43 | 0.001 |       |

OC: ovarian cancer; OSC: osteosarcoma; GC: gastric cancer; CCA: cholangiocarcinoma; ESCC: esophageal squamous cell carcinoma; BC: breast cancer; others including colorectal cancer, pancreatic cancer, hepatocellular carcinoma, gallbladder cancer, and non-small cell lung cancer; F: fixed effects; R: random effects; NR: none reported; OS: overall survival; DFS: disease-free survival; HR: hazard ratio; CI: confidence interval; $P_h$: $P$ value for heterogeneity based on Q test; $P_m$: $P$ value for statistical outcome based on multivariate metaregression analysis.
| ID            | HR (95% Cl) | Weight |
|---------------|-------------|--------|
| Sienko J 2019 | 3.57 (1.41, 9.09) | 4.46   |
| Cai AL (T) 2018 | 1.94 (1.20, 3.14) | 6.49   |
| Cai AL (V) 2018 | 2.26 (1.29, 3.97) | 6.12   |
| Li HX 2018    | 1.75 (1.01, 3.05) | 6.17   |
| Zhang MJ 2018 | 10.03 (1.96, 51.46) | 2.37   |
| Yu W 2018     | 2.43 (1.43, 4.13) | 6.27   |
| Zhou J 2015   | 2.60 (1.11, 6.06) | 4.82   |
| Wu JP 2015    | 1.19 (0.62, 2.30) | 5.67   |
| Cai CY 2015   | 3.16 (1.42, 7.02) | 5.04   |
| Xu DY 2014    | 1.77 (1.12, 2.61) | 6.75   |
| O'Leary PC (RPPA) 2014 | 0.93 (0.66, 1.31) | 7.07   |
| O'Leary PC (TMA) 2014 | 0.76 (0.46, 1.03) | 7.20   |
| Sun QK 2014   | 2.90 (1.36, 6.19) | 5.21   |
| Li J 2013     | 2.12 (1.27, 3.56) | 6.33   |
| Yonglithipagon P 2012 | 0.66 (0.50, 0.88) | 7.28   |
| Kim JH 2007   | 2.41 (1.29, 4.50) | 5.83   |
| Hoshimo J 2007 | 0.64 (0.44, 0.94) | 6.91   |
| Overall (I² = 76.8%, P = 0.000) | 1.68 (1.24, 2.27) | 100.00 |

Note: weights are from random effects analysis

**Figure 2:** Forest plots of the overall outcomes for overall survival (OS). Hazard ratios (HRs) for each trial are represented by the squares, and the horizontal lines crossing the square stand for the 95% confidence intervals (CIs). The diamonds represent the estimated pooled effect of the overall outcome for OS in all solid tumors. All P values are two-sided.

| ID            | HR (95% Cl) | Weight |
|---------------|-------------|--------|
| Sienko J 2019 | 2.63 (1.19, 6.25) | 7.72   |
| Cai AL (T) 2018 | 1.85 (1.19, 2.86) | 11.47  |
| Cai AL (V) 2018 | 2.21 (1.37, 3.56) | 11.12  |
| Yu W 2018     | 2.47 (1.46, 4.18) | 10.65  |
| Zhou J 2015   | 1.34 (0.60, 2.99) | 8.22   |
| Cai CY 2015   | 4.80 (2.14, 10.81) | 8.14   |
| O'Leary PC (RPPA) 2014 | 0.94 (0.65, 1.35) | 12.08  |
| O'Leary PC (TMA) 2014 | 0.78 (0.52, 1.16) | 11.78  |
| Sun QK 2014   | 3.27 (1.53, 6.97) | 8.59   |
| Kim JH 2007   | 2.33 (1.31, 4.13) | 10.24  |
| Overall (I² = 82.9%, P = 0.000) | 1.88 (1.31, 2.70) | 100.00 |

Note: weights are from random effects analysis

**Figure 3:** Forest plots of the overall outcomes for disease-free survival (DFS). Hazard ratios (HRs) for each trial are represented by the squares, and the horizontal lines crossing the square stand for the 95% confidence intervals (CIs). The diamonds represent the estimated pooled effect of the overall outcome for DFS in all solid tumors. All P values are two-sided.
Figure 4: Effects of individual studies on pooled hazard ratios (HRs) for PRDX1 and survival in solid tumors. (a) Result of sensitivity analysis for pooled OS estimation. (b) Result of sensitivity analysis for pooled DFS estimation.

Figure 5: Begg's funnel plots for assessment of potential publication bias in studies of PRDX1 in patients with solid tumor. Each study represented by one circle. The horizontal line represented the pooled effect estimate. (a) Funnel plot of publication bias for overall survival. (b) Funnel plot adjusted with trim-and-fill methods for overall survival. (c) Funnel plot of publication bias for disease-free survival. (d) Funnel plot adjusted with trim-and-fill methods for studies reporting disease-free survival.
PRDX1 is a multifunctional protein that acts as a hydrogen peroxide scavenger, molecular chaperone, and immune modulator [29]. The relationship between PRDX1 expression level and prognosis of patients with solid tumors has been studied; however, the prognostic value of PRDX1 remains highly ambiguous. Therefore, we performed this meta-analysis to critically assess the prognostic significance of PRDX1 expression.

In our meta-analysis, we pooled 17 cohort studies involving 2,858 patients with solid cancer. Our overall pooled results indicated that high PRDX1 expression could predict poor OS (HR = 1.68, 95% CI: 1.24–2.27, \( P = 0.001 \)) and DFS (HR = 1.88, 95% CI: 1.31–2.70, \( P = 0.001 \)). Hence, high PRDX1 expression could indicate poor prognosis in solid cancers. However, the combined results may be challenged because of significant heterogeneity. To explore the source of heterogeneity for OS, we conducted subgroup and meta-regression analyses according to study region, cancer type, TNM stage, sample size, and analysis method. Sample size and analysis method may significantly explain the heterogeneity for the combined HR of OS, and the heterogeneity mainly originated from the studies of O’Leary et al. [29], Yonglitthipagon et al. [25], and Hoshino et al. [27]. Furthermore, sensitivity analysis and publication bias assessment were conducted to verify the stability and reliability of the combined results for OS and DFS. The sensitivity analysis suggested the absence of point estimate of the omitted individual dataset outside the 95% CI of the combined analyses. Despite the existence of significant publication bias, the trim-and-fill analysis confirmed that it had no strong effect on the pooled results of the meta-analysis.

To further verify the prognostic effect of PRDX1 on malignant tumors, we analyzed the correlation between PRDX1 expression and clinicopathological features that might affect survival outcomes. According to the pooled results, high PRDX1 expression was associated with large tumor size, advanced TNM stage, and poor tumor differentiation. No statistically significant correlations were found for age, gender, depth of invasion, lymph node metastasis, and distant metastasis. PRDX1 overexpression was related to poor prognosis and tumor invasiveness in solid cancers. The possible reasons for these results are as follows:

First, as an endogenous product of aerobic respiration in all metazoan organisms, ROS is involved not only in tumor metastasis but also in tumorigenesis [33, 34]. PRDX1 directly affects tumor suppression by eliminating ROS and preventing oxidative damage to DNA [35]. However, PRDX1 and other peroxidases have been reported to be overexpressed in some human solid tumors, thereby suggesting that tumors generated by other mechanisms may benefit from increased peroxidases [35]. PRDX1 cooperates with thioredoxin in inhibiting ROS-induced tumor cell apoptosis and promoting tumor cell survival by involving different types of kinases and enzymes, such as apoptosis signal-regulating kinase 1, p66Shc, and glutathione S-transferase pi (GSTpi)/c-Jun NH2-terminal kinase (JNK) [19, 36]. In addition, PRDX1 is considered a physiological inhibitor of c-Abl tyrosine kinase by binding to the SH-3 domain of c-Abl. c-Abl is an upstream effector molecule of the JNK and p38 mitogen-activated protein kinase pathway and plays a key role in oxidative stress-induced cell death [37]. Therefore, PRDX1 may inhibit stress-induced cell death through ROS-dependent signaling pathways [19]. The role of oxidative stress in ER-positive breast cancer may differ from those in other types of tumors. Physiological estrogen concentration can induce ROS production, which is the main carcinogenesis mechanism related to estrogen; as such, the ROS scavenging system is predicted to play an important role. Therefore, PRDX1 may be an independent predictor of improved prognosis of ER-positive breast cancer (which differs from other cancers) [29, 38]. Moreover, any possible PRDX1 inhibitors should be carefully explored in ER-positive breast cancer because they may transform tumor cells into a more aggressive phenotype with poor prognosis. This situation is also the main source of heterogeneity in this meta-analysis. The possible reasons of heterogeneity caused by two articles in this work were as follows: the HR in one study was not adjusted for confounding factors, and patients in the other article were infected with liver fluke.

Second, previous studies revealed that PRDX1 excessive expression enhances epithelial-mesenchymal transition (EMT) by inducing transforming growth factor beta 1; EMT is regarded as a critical process in tumor invasion and metastasis [39]. During EMT, malignant tumor cells lose their own epithelial properties and acquire the characteristics of mesenchymal cells, thereby causing the dissociation of tumor cells from primary carcinomas and promoting their subsequent migration and dissemination to distant sites [22, 40]. EMT is also an important event in the tumor microenvironment, and various components of such microenvironment provide suitable conditions for EMT [28, 41].

Third, the extracellular matrix (ECM) is a component of the tumor microenvironment, and its degradation is essential for tumor cells to escape from primary lesions. The matrix metalloproteinase (MMP) family can degrade the major components of the ECM and plays an important role in promoting tumor invasion and metastasis [42]. Among MMP types, MMP2 and MMP9 promote the invasion and metastasis of tumor cells by degrading type IV collagen, a main component of the ECM [21]. A study of 180 patients with CRC showed that MMP2 and MMP9 overexpression was associated with poor prognosis [43]. Moreover, MMP could be activated by PRDX1 to cause tumor cell metastasis [21].

Fourth, the invasion and metastasis of tumor cells are a complex series of pathophysiological processes accompanied by a complex regulatory network involving multiple molecules. In addition to the signaling pathways mentioned above, those
related to PRDX1 are involved in the p53 signaling pathway, Akt/mTOR signaling pathway, PI3K/Akt signaling pathway, pathways in cancer, FoxO signaling pathway, cell cycle, and ubiquitin-mediated proteolysis [8, 20, 44].

This meta-analysis presents certain limitations, and the results should be interpreted with caution. To begin with, the cut-off value of positive and negative PRDX1 expression was inconsistent among different studies, leading to bias in the results. Second, several individual HRs could not be directly achieved from the published data, resulting in some errors. Third, studies with positive results were more likely to be published than those with negative results. This phenomenon may lead to publication bias and exaggerate the overall results. Fourth, only published articles in English and Chinese were enrolled. Fifth, all included cohort studies were retrospective. Prospective studies are needed to assess the prognostic value of PRDX1 expression in patients with solid tumors. Finally, prospective studies are needed to assess the prognostic value of PRDX1 expression in patients with solid tumors.

Acknowledgments

This study was funded by the Taizhou People’s Hospital Medical Innovation Team Foundation (CXTDA201901, CXTDA201904) and Taizhou People’s Hospital Mandatory Project (ZL201809).

Data Availability

The data supporting this meta-analysis are from previously reported studies and datasets, which have been cited. The processed data are available within the article.

Conflicts of Interest

The authors report no conflicts of interest in this work.

Acknowledgments

This study was funded by the Taizhou People’s Hospital Medical Innovation Team Foundation (CXTDA201901, CXTDA201904) and Taizhou People’s Hospital Mandatory Project (ZL201809).

References

[1] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer Statistics, 2018,” CA: a Cancer Journal for Clinicians, vol. 68, no. 1, pp. 7–30, 2018.

[2] L. Hu, Y. Zha, F. Kong, and Y. Pan, “Prognostic value of high stanniocalcin 2 expression in solid cancers,” Medicine, vol. 98, no. 43, article e17432, 2019.

[3] J. Song, X. Chen, Q. Tian et al., “The value of IncRNA GHET1 as a prognostic factor for survival of Chinese cancer outcome: a meta-analysis,” Disease Markers, vol. 2019, 7 pages, 2019.

[4] G. Y. Lv, L. An, and D. W. Sun, “Geriatric nutritional risk index predicts adverse outcomes in human malignancy: a meta-analysis,” Disease Markers, vol. 2019, Article ID 4796598, 13 pages, 2019.

[5] B. Hu, H. Fan, X. Lv, S. Chen, and Z. Shao, “Prognostic significance of CXCL5 expression in cancer patients: a meta-analysis,” Cancer Cell International, vol. 18, no. 1, p. 68, 2018.

[6] M. Schafer and S. Werner, “Oxidative stress in normal and impaired wound repair,” Pharmacological Research, vol. 58, no. 2, pp. 165–171, 2008.

[7] Y. Kim and H. H. Jang, “The role of peroxiredoxin family in cancer signaling,” Journal of Cancer Prevention, vol. 24, no. 2, pp. 65–71, 2019.

[8] M. Zheng, J. Wang, H. M. Wang et al., “Decreased expression of peroxiredoxin1 inhibits proliferation, invasion, and metastasis of ovarian cancer cell,” Oncotargets and Therapy, vol. 11, pp. 7745–7761, 2018.

[9] R. A. Poynton and M. B. Hampton, “Peroxiredoxins as biomarkers of oxidative stress,” Biochimica et Biophysica Acta (BBA) - General Subjects, vol. 1840, no. 2, pp. 906–912, 2014.

[10] L. Chen, C. Huang, X. Yang, Q. Zhang, and F. Chen, “Prognostic roles of mRNA expression of peroxiredoxins in lung cancer,” Oncotargets and Therapy, vol. 11, pp. 8381–8388, 2018.

[11] B. Kim, Y. S. Kim, H. M. Ahn et al., “Peroxiredoxin 5 overexpression enhances tumorigenicity and correlates with poor prognosis in gastric cancer,” International Journal of Oncology, vol. 51, no. 1, pp. 298–306, 2017.

[12] J. Sienko, J. Teliga-Czajkowska, E. Przytula, K. Czajkowski, R. Smolarczyk, and D. Nowis, “Peroxiredoxin-1 as a prognostic factor in patients with ovarian cancer,” Annals of Agricultural and Environmental Medicine, vol. 26, no. 3, pp. 415–419, 2019.

[13] J. Sienko, P. Gaj, K. Czajkowski, and D. Nowis, “Peroxiredoxin-5 is a negative survival predictor in ovarian cancer,” Ginekologia Polska, vol. 90, no. 1, pp. 1–6, 2019.

[14] H. C. Whitaker, D. Patel, W. J. Howat et al., “Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress,” British Journal of Cancer, vol. 109, no. 4, pp. 983–993, 2013.

[15] Z. A. Wood, E. Schröder, J. R. Harris, and L. B. Poole, “Peroxiredoxin involvement in the initiation and progression of human cancer,” Antioxidants & Redox Signaling, vol. 28, no. 7, pp. 591–608, 2018.

[16] M. B. Hampton, K. A. Vick, J. J. Skoko, and C. A. Neumann, “Peroxiredoxin involvement in the initiation and progression of human cancer,” Antioxidants & Redox Signaling, vol. 28, no. 7, pp. 591–608, 2018.

[17] R. R. Chhipa, K. S. Lee, S. Onate, Y. Wu, and C. Ip, “Prx1 enhances androgen receptor function in prostate cancer cells by increasing receptor affinity to dihydrotestosterone,” Molecular Cancer Research, vol. 7, no. 9, pp. 1543–1552, 2009.

[18] M. Zhang, M. Hou, L. Ge et al., “Induction of peroxiredoxin 1 by hypoxia regulates heme oxygenase-1 via NF-κB in oral cancer,” PLoS One, vol. 9, no. 8, article e105994, 2014.

[19] C. Ding, X. Fan, and G. Wu, “Peroxiredoxin 1 - an antioxidant enzyme in cancer,” Journal of Cellular and Molecular Medicine, vol. 21, no. 1, pp. 193–202, 2017.

[20] A. L. Cai, W. Zeng, W. L. Cai et al., “Peroxiredoxin-1 promotes cell proliferation and metastasis through enhancing Akt/mTOR in human osteosarcoma cells,” Oncotarget, vol. 9, no. 9, pp. 8290–8302, 2018.
[21] H. X. Li, X. Y. Sun, S. M. Yang, Q. Wang, and Z. Y. Wang, "Peroxiredoxin 1 promoted tumor metastasis and angiogenesis in colorectal cancer," *Pathology, Research and Practice*, vol. 214, no. 5, pp. 655–660, 2018.

[22] W. Yu, J. Wu, Z. Ning, Q. Y. Liu, and R. L. Quan, "High expression of peroxiredoxin 1 is associated with epithelial-mesenchymal transition marker and poor prognosis in gastric cancer," *Medical Science Monitor*, vol. 24, pp. 2259–2270, 2018.

[23] D. Y. Xu, X. J. He, J. J. Wang et al., "Expression of PRDX1 in gastric cancer and its clinical significance," *Chinese Clinical Oncology*, vol. 19, no. 5, pp. 417–420, 2014.

[24] J. Zhou, W. Shen, X. He, J. Qian, S. Liu, and G. Yu, "Overexpression of Prdx1 in hilar cholangiocarcinoma: a predictor for recurrence and prognosis," *International Journal of Clinical and Experimental Pathology*, vol. 8, no. 9, pp. 9863–9874, 2015.

[25] P. Yonglitthipagon, C. Pairojkul, Y. Chamgramol et al., "Peroxiredoxin 1 and ezrin-radixin-moesin-binding phosphoprotein 50 in cholangiocarcinoma," *Human Pathology*, vol. 43, no. 10, pp. 1719–1730, 2012.

[26] J. P. Wu, F. Jiang, L. Yu, and X. H. Pan, "Expression of PRDX1 in esophageal squamous cell carcinoma and the significance," *Hepat Medicine*, vol. 21, no. 8, pp. 1408–1411, 2015.

[27] I. Hoshino, H. Matsubara, Y. Akutsu et al., "Tumor suppressor Prdx1 is a prognostic factor in esophageal squamous cell carcinoma patients," *Oncology Reports*, vol. 18, no. 4, pp. 867–871, 2007.

[28] C. Y. Cai, L. L. Zhai, Y. Wu, and Z. G. Tang, "Expression and clinical value of peroxiredoxin-1 in patients with pancreatic cancer," *European Journal of Surgical Oncology (EJSO)*, vol. 41, no. 2, pp. 228–235, 2015.

[29] P. C. O’Leary, M. Terrile, M. Bajor et al., "Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer," *Breast Cancer Research*, vol. 16, no. 4, p. R79, 2014.

[30] Q. K. Sun, J. Y. Zhu, W. Wang et al., "Diagnostic and prognostic significance of peroxiredoxin 1 expression in human hepatocellular carcinoma," *Medical Oncology*, vol. 31, no. 1, p. 786, 2014.

[31] J. Li, Z. Yang, X. Ren et al., "ILK and PRDX1 are prognostic markers in squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder," *Tumor Biology*, vol. 34, no. 1, pp. 359–368, 2013.

[32] J. H. Kim, P. N. Bogner, N. Ramnath, Y. Park, J. Yu, and Y. M. Park, "Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer," *Clinical Cancer Research*, vol. 13, no. 13, pp. 3875–3882, 2007.

[33] S. Galadari, A. Rahman, S. Pallichankandy, and F. Thayyullathil, "Reactive oxygen species and cancer paradox: to promote or to suppress?", *Free Radical Biology and Medicine*, vol. 104, pp. 144–164, 2017.

[34] S. Prasad, S. C. Gupta, and A. K. Tyagi, "Reactive oxygen species (ROS) and cancer: role of antioxidative nutraceuticals," *Cancer Letters*, vol. 387, pp. 95–105, 2017.

[35] C. A. Neumann, D. S. Krause, C. V. Carman et al., "Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression," *Nature*, vol. 424, no. 6948, pp. 561–565, 2003.

[36] M. Gertz, F. Fischer, M. Leipelt, D. Wolters, and C. Steegborn, "Identification of peroxiredoxin 1 as a novel interaction partner for the lifespan regulator protein p66Shc," *Aging*, vol. 1, no. 2, pp. 254–265, 2009.

[37] T. Ishii, E. Warabi, and T. Yanagawa, "Novel roles of peroxiredoxins in inflammation, cancer and innate immunity," *Journal of Clinical Biochemistry and Nutrition*, vol. 50, no. 2, pp. 91–105, 2012.

[38] J. Sastre-Serra, A. Valle, M. M. Company, I. Garau, J. Oliver, and P. Roca, "Estrogen down-regulates uncoupling proteins and increases oxidative stress in breast cancer," *Free Radical Biology and Medicine*, vol. 48, no. 4, pp. 506–512, 2010.

[39] L. Jiao, D. D. Li, C. L. Yang et al., "Reactive oxygen species mediate oxaliplatin-induced epithelial-mesenchymal transition and invasive potential in colon cancer," *Tumor Biology*, vol. 37, no. 6, pp. 8413–8423, 2016.

[40] H. J. Maier, T. Wirth, and H. Beug, "Epithelial-mesenchymal transition in pancreatic carcinoma," *Cancers*, vol. 2, no. 4, pp. 2058–2083, 2010.

[41] N. Bezdenezhnykh, N. Semesiuk, O. Lykhova, V. Zhychkuk, and Y. Kudryavets, "Impact of stromal cell components of tumor microenvironment on epithelial-mesenchymal transition in breast cancer cells," *Experimental Oncology*, vol. 36, no. 2, pp. 72–78, 2014.

[42] G. T. Brown and G. I. Murray, "Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis," *The Journal of Pathology*, vol. 237, no. 3, pp. 273–281, 2015.

[43] R. F. Araújo Jr., G. A. Lira, J. A. Vilaça et al., "Prognostic and diagnostic implications of MMP-2, MMP-9, and VEGF-α expressions in colorectal cancer," *Pathology - Research and Practice*, vol. 211, no. 1, pp. 71–77, 2015.

[44] A. Yerlikaya and M. Yöntem, "The significance of ubiquitin proteasome pathway in cancer development," *Recent Patents on Anti-Cancer Drug Discovery*, vol. 8, no. 3, pp. 298–309, 2013.